ArticleTropical medicine and health2026
Diversity and perceptions about side effects of medicinal plants used by herbalists to treat gastrointestinal diseases in Sironko District, Eastern Uganda.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe escalation of gastrointestinal tract (GIT) illnesses is now a major global threat, with countries like Uganda having a prevalence of over 31 %. Herbal medicines (HM) are widely used to treat GIT illnesses in many low-resource settings including Sironko District in Eastern Uganda, but their safety remains a grave concern because they often contain bioactive phytochemicals that may cause harmful side effects. In Sironko, herbalists commonly rely on indigenous knowledge rather than formal pharmacological training when prescribing HM hence the potential for adverse reactions linked to toxic phytocompounds is substantial, warranting comprehensive scientific investigation.
objectiveTo explore plant species used to treat GIT illnesses and perceptions of their adverse effects in Sironko District, to inform safer herbal medicine use.
methodsA sample of 70 herbalists was subjected to an ethnobotanical survey using pre-validated semi-structured questionnaires to profile plant species primarily used against GIT illnesses plus awareness and perceptions about the associated side effects. Data were analyzed with descriptive and inferential statistics using STATA version-15.0. Graphs were plotted with GraphPad Prism
resultsA total of 80 plants species used against GIT infections were documented, mainly in families; Asteraceae and Euphorbiaceae, indicated for treatment and prevention of 24 gastrointestinal illnesses, mostly diarrhea (18.94%), ulcers (11.81%), and stomachaches (8.52%), plus 39 ailments affecting other body systems. Informant consensus factors were high for all disease categories (≥ 0.630), showing homogeneity of ethnomedicinal knowledge. Chenopodium opulifolium, Tithonia diversifolia and Senna didymobotrya were reported to pose the greatest number of side effects, including headache and insomnia. The 70% of participants were unaware that HM can be toxic, 57% were certain that HM do not have side effects, yet those that opposed the need for urgent action against HM adversity were significantly more than participants who perceived it as vital (χ
conclusionThere is a high diversity of plant species used to treat primarily GIT illnesses in Sironko, but many potentially stimulate life-threatening adverse effects such as severe headache and vomiting. These results highlight a need for considerable investment in herbal medicine safety to leverage its optimal use in health promotion and economic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.